NCT05033002

Brief Summary

This study will test a stigma reduction intervention with women living with HIV in Tanzania.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
167

participants targeted

Target at P25-P50 for not_applicable hiv

Timeline
Completed

Started Oct 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 31, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 2, 2021

Completed
1.1 years until next milestone

Study Start

First participant enrolled

October 24, 2022

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 16, 2024

Completed
12 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 28, 2024

Completed
1 year until next milestone

Results Posted

Study results publicly available

May 29, 2025

Completed
Last Updated

May 29, 2025

Status Verified

May 1, 2025

Enrollment Period

1.6 years

First QC Date

August 31, 2021

Results QC Date

May 7, 2025

Last Update Submit

May 27, 2025

Conditions

Keywords

HIVwomen living with HIVclinical trialTanzaniaefficacyfeasibility

Outcome Measures

Primary Outcomes (5)

  • Number of Participants Recruited as Measured by Enrollment Logs

    up to 6 months

  • Number of Study Participants Retained in Study as Measured by Enrollment Logs

    30, 90, and 180 days after intervention

  • Percent of Questions Left Blank on Study Instruments

    baseline and 30, 90, and 180 days after intervention

  • Time it Takes in Minutes for Participants to Complete the Questionnaires

    baseline and 30, 90, and 180 days after intervention

  • Number of Women Who Completed All 5 Sessions

    up to 5 weeks

Secondary Outcomes (5)

  • Change in Internalized Stigma, as Measured by the Swahili Version of the Multidimensional Measure of Internalized Stigma Scale

    baseline and 30, 90, and 180 days after intervention

  • Change in Coping Self-efficacy, as Measured by the Swahili Version of the Coping Self-Efficacy Scale

    baseline and 30, 90, and 180 days after intervention

  • Change in Self-esteem, as Measured by the Swahili Version of the Rosenberg Self-Esteem Scale

    baseline and 30, 90, and 180 days after intervention

  • Hope, as Measured by the Swahili Version of the State of Hope Scale

    Baseline

  • Change in Depressive Symptoms, as Measured by the Swahili Version of the Patient Health Questionnaire 9

    baseline and 30, 90, and 180 days after intervention

Study Arms (2)

Treatment as Usual Group

NO INTERVENTION

This group will receive treatment as usual which means that no formal stigma reduction intervention will be provided. At the end of the follow-up period, this group will be invited to view the Labda Siku Moja stigma reduction intervention without follow-up.

Stigma Intervention Group

EXPERIMENTAL

This group will participate in a 5 week intervention. Each week, intervention group participants will watch one ethnodrama segment of the Labda Siku Moja stigma reduction intervention followed by a guided debrief using motivational interviewing.

Behavioral: Labda Siku Moja stigma reduction intervention

Interventions

The Labda Siku Moja stigma reduction intervention is a tailored stigma reduction intervention for women living with HIV in Tanzania. It is comprised of five ethnodramas (video stories) culturally and linguistically relevant to the Tanzanian women living with HIV.

Stigma Intervention Group

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • (1) women who are living with HIV;
  • (2) age 18 (age of adulthood as defined by the Tanzanian government);
  • (3) able and willing to voluntarily consent to participate in the study;
  • (4) able to travel to a data collection in their local community (as described above);
  • (5) demonstrate mental competence at time of informed consent;
  • (6) verbally indicate that they plan to reside in their current community for at least 6 months after enrollment (necessary to prevent attrition);
  • (7) score at the median or higher level on the Swahili Version of the Multidimensional Measure of Internalized HIV Stigma Scale.

You may not qualify if:

  • (1) any acute psychological or physiological distress; if there is evidence of acute psychologic and/or physiologic, they will be excluded from this study and referred to an appropriate site for evaluation and treatment.
  • (2) Transgender women living with HIV will not be eligible to participate in this study to reduce the potential for confounding sources of stigma recognizing that a transgender identity is highly stigmatized and culturally sensitive in Tanzania. Further, it would be exceedingly difficult to recruit a sufficient sample of transgender women living with HIV to conduct an appropriate analysis.
  • (3) Participants may be enrolled in other HIV-related studies except cognitive-behavioral intervention studies addressing stigma, self-efficacy, self-esteem, and/or disclosure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Muhimbili University of Health and Allied Sciences

Dar es Salaam, Tanzania

Location

Related Publications (1)

  • Nyblade L, Kilonzo MN, Kisamo DH, Mtei RJ, Pan W, Relf MV. Efficacy Testing of a Culturally Relevant Stigma Reduction Intervention for Women Living With HIV in Tanzania: Protocol for a Randomized Controlled Trial. J Assoc Nurses AIDS Care. 2025 Mar 26;36(5):470-481. doi: 10.1097/JNC.0000000000000538.

MeSH Terms

Conditions

Social StigmaDepression

Condition Hierarchy (Ancestors)

Social BehaviorBehaviorBehavioral Symptoms

Results Point of Contact

Title
Michael Relf, Ph.D.
Organization
Duke University School of Nursing

Study Officials

  • Michael V. Relf, PhD

    Duke University School of Nursing

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 31, 2021

First Posted

September 2, 2021

Study Start

October 24, 2022

Primary Completion

May 16, 2024

Study Completion

May 28, 2024

Last Updated

May 29, 2025

Results First Posted

May 29, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations